U.S Pharmaceutical Third-Party Logistics Services Market Growth, Size, Trends & Analysis 2034
U.S Pharmaceutical Third-Party Logistics Services Market Growth, Size, Trends Analysis- By Product Type, By Temperature, By Therapeutic Area, By Manufacturer Size- Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Jul-2025 | Report ID: HLCA25246 | Pages: 1 - 260 | Formats*: |
| Category : Healthcare | |||
U.S Pharmaceutical Third-Party Logistics Services Market Introduction and Overview
According to SPER Market Research, the U.S Pharmaceutical Third-Party Logistics Services Market is estimated to reach USD 109.76 billion by 2034 with a CAGR of 9.15%.
The report includes an in-depth analysis of the U.S Pharmaceutical Third-Party Logistics Services Market, including market size and trends, product mix, Applications, and supplier analysis. The U.S Pharmaceutical Third-Party Logistics Services market is expected to be worth USD 45.73 billion in 2024, with a CAGR of 9.15% between 2025 and 2034. In recent years, the Pharmaceutical Third-Party Logistics (3PL) Services industry in the United States has undergone substantial growth and transformation. The adoption of advanced technologies, precision logistics solutions, and customer-centric service models has redefined industry benchmarks for compliance, efficiency, and reliability. Growing demand across segments such as biologics, specialty drugs, and temperature-sensitive therapies has driven continuous improvement in cold chain capabilities and real-time tracking systems.
By Product Type Insights
The Branded segment holds a leading position in the pharmaceutical third-party logistics market. This dominance is driven by the growing incidence of chronic diseases such as diabetes, hypertension, and cardiovascular conditions. As these health issues continue to rise across the U.S., the demand for branded drugs has significantly increased. Branded medications are often preferred due to their proven efficacy, strong market presence, and physician trust, further strengthening the need for reliable and specialized logistics support to ensure timely and safe delivery.
By Temperature Insights
The Ambient segment holds a prominent position in the pharmaceutical third-party logistics market, driven by the rising demand for efficient transportation and storage of non-temperature-sensitive pharmaceutical products. As pharmaceutical companies increasingly seek reliable and cost-effective distribution solutions for drugs that do not require cold chain logistics, ambient 3PL services have become vital. These services support timely delivery, lower operational costs, and optimized supply chain performance. Furthermore, advancements in logistics technologies—such as real-time tracking, data analytics, and enhanced warehouse management systems—have significantly improved the efficiency, accuracy, and competitiveness of ambient logistics solutions, making them an integral part of the pharmaceutical supply chain.
By Therapeutic Area Insight
The Oncology segment holds a leading position in the pharmaceutical third-party logistics market and is expected to continue expanding due to the rising number of cancer cases across the United States. The pharmaceutical industry has witnessed notable advancements in cancer treatment, including the development of innovative chemotherapy, immunotherapy, and targeted therapy approaches. These innovations have significantly increased the demand for specialized logistics solutions capable of handling complex and sensitive oncology drugs. Additionally, growing pharmaceutical R&D investments, the introduction of new biologics, and the expiration of patents are further driving demand in this segment. As a result, 3PL providers are adapting their services to support the evolving needs of oncology drug distribution, including enhanced cold chain logistics, regulatory compliance, and precise inventory management.
By Manufacturer Size Insight
The Large segment holds a dominant position in the U.S. pharmaceutical third-party logistics (3PL) services industry. Large pharmaceutical manufacturers possess extensive resources, well-established supply chains, and significant production capacities. With broad product portfolios, these companies are able to negotiate favorable contracts with logistics providers and demand high levels of service efficiency. Their scale also allows them to implement advanced technologies for inventory management, real-time tracking, and streamlined distribution processes. This results in optimized supply chain performance, improved delivery timelines, and reduced operational costs. The ability to invest in innovation and infrastructure further strengthens their influence within the 3PL landscape.
By Region Insights
The U.S Pharmaceutical Third-Party Logistics Services Market is separated into four regional segments: Northeast, Midwest, West, and South. The Southern region is currently leading the market. This is largely due to the presence of major Pharmaceutical Third-Party Logistics Services companies, robust research and development (R&D) infrastructure, and high healthcare expenditure in these areas.
Market Competitive Landscape
The U.S Pharmaceutical Third-Party Logistics Services Industry has major players, including Cardinal Health, Cencora Corporation (ICS), CEVA Logistics, DB SCHENKER, EVERSANA, Kerry Logistics Network Limited, Knipper Health, Kuehne+Nagel, McKesson Corporation, Thermo Fisher Scientific. These companies compete fiercely with each other and local firms that have strong distribution networks and knowledge of suppliers and regulations. CEVA Logistics is a leading global 3PL provider and a subsidiary of CMA CGM Group, headquartered in Marseille, France. Founded in 2007 from the merger of TNT Logistics and EGL Eagle Global Logistics, CEVA now operates across 1,300+ facilities in 170 countries, with around 110,000 employees delivering end-to-end supply chain, freight management, and contract logistics services.
Recent Developments:
In November 2024: Kuehne+Nagel strengthened its presence in North America's logistics landscape by acquiring a 51% stake in IMC Logistics, a prominent U.S. marine drayage provider specializing in seamless transportation between seaports, rail hubs, and inland facilities. This strategic move enhances Kuehne+Nagel’s capabilities in end-to-end logistics, providing greater flexibility and resilience in response to ongoing supply chain disruptions and increasing demand for integrated transport solutions.
In July 2024: CEVA Logistics, a subsidiary of the CMA CGM Group, implemented a new organizational structure aimed at simplifying customer access to its comprehensive global logistics services. This restructuring enhances the efficiency and integration of its offerings across air, ocean, ground, and rail transport, as well as contract logistics, finished vehicle logistics, project logistics, and customs solutions. The move is designed to deliver more agile, customer-focused solutions by aligning operations with evolving market demands and streamlining service delivery across all major logistics segments.
In May 2023: Yaral Pharma, the U.S. generics subsidiary of IBSA, has strengthened its partnership with EVERSANA to advance the commercialization of its pain and endocrinology portfolio in the United States. Through this expanded collaboration, EVERSANA is providing end-to-end support, including third-party logistics (3PL) and operational services, to ensure streamlined distribution, enhanced customer service, and effective market penetration. This strategic alliance underscores both companies' commitment to improving patient access and optimizing commercial outcomes across key therapeutic areas.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product Type, By Temperature, By Therapeutic Area, By Manufacture Size |
| Regions covered | Northeast, Midwest, West, South |
| Companies Covered | Cardinal Health, Cencora Corporation (ICS), CEVA Logistics, DB SCHENKER, EVERSANA, Kerry Logistics Network Limited, Knipper Health, Kuehne+Nagel, McKesson Corporation, Thermo Fisher Scientific. |
Key Topics Covered in the Report
- U.S Pharmaceutical Third-Party Logistics Services Market Size (FY’2021-FY’2034)
- Overview of U.S Pharmaceutical Third-Party Logistics Services Market
- Segmentation of U.S Pharmaceutical Third-Party Logistics Services Market, By Product Type (Branded, Generic, Biosimilar, Vaccine, Cell Therapy, Gene Therapy, Others)
- Segmentation of U.S Pharmaceutical Third-Party Logistics Services Market, By Temperature (Ambient, Refrigerated, Frozen, Ultra-Frozen/Deep-Frozen, Cryogenic)
- Segmentation of U.S Pharmaceutical Third-Party Logistics Services Market, By Therapeutic Area (Oncology, Cardiovascular Diseases, Infectious Diseases, Neurology, Diabetes, Nephrology, Rheumatology, Asthma, Others)
- Segmentation of U.S Pharmaceutical Third-Party Logistics Services Market, By Manufacturer Size (Large, Medium, Small)
- Statistical Snap of U.S Pharmaceutical Third-Party Logistics Services Market
- Expansion Analysis of U.S Pharmaceutical Third-Party Logistics Services Market
- Problems and Obstacles in U.S Pharmaceutical Third-Party Logistics Services Market
- Competitive Landscape in the U.S Pharmaceutical Third-Party Logistics Services Market
- Details on Current Investment in U.S Pharmaceutical Third-Party Logistics Services Market
- Competitive Analysis of U.S Pharmaceutical Third-Party Logistics Services Market
- Prominent Players in the U.S Pharmaceutical Third-Party Logistics Services Market
- SWOT Analysis of U.S Pharmaceutical Third-Party Logistics Services Market
- U.S Pharmaceutical Third-Party Logistics Services Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPERs internal database2.1.4.Premium insight from KOLs2.2.Market size estimation2.2.1.Top-down and Bottom-up approach2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis
4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges
5.Market variable and outlook
5.1.SWOT Analysis5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats5.2.PESTEL Analysis5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape5.2.5.Environmental Landscape5.2.6.Legal Landscape5.3.PORTERs Five Forces5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry5.4.Heat Map Analysis
6.Competitive Landscape
6.1.U.S Pharmaceutical Third-Party Logistics Services Market Manufacturing Base Distribution, Sales Area, Temperature Therapeutic Area6.2.Mergers & Acquisitions, Partnerships, Temperature Launch, and Collaboration in U.S Pharmaceutical Third-Party Logistics Services Market
7.U.S Pharmaceutical Third-Party Logistics Services Market, By Product Type 2021-2034 (USD Million)
7.1.Branded7.2.Generic7.3.Biosimilar7.4.Vaccine7.5.Cell Therapy7.6.Gene Therapy7.7.Others
8.U.S Pharmaceutical Third-Party Logistics Services Market, By Temperature 2021-2034 (USD Million)
8.1.Ambient8.2.Refrigerated8.3.Frozen8.4.Ultra-Frozen/Deep-Frozen8.5.Cryogenic
9.U.S Pharmaceutical Third-Party Logistics Services Market, By Therapeutic Area 2021-2034 (USD Million)
9.1.Oncology9.2.Cardiovascular Diseases9.3.Infectious Diseases9.4.Neurology9.5.Diabetes9.6.Nephrology9.7.Rheumatology9.8.Asthma9.9.Others
10. U.S Pharmaceutical Third-Party Logistics Services Market, By Manufacturer Size 2021-2034 (USD Million)
10.1.Large10.2.Medium10.3.Small
11.U.S Pharmaceutical Third-Party Logistics services Market, 2021-2034 (USD Million)
11.1.U.S Pharmaceutical Third-Party Logistics services Market Size and Market Share
12.U.S Pharmaceutical Third-Party Logistics services Market, By Region, 2021-2034 (USD Million)
12.1.Northeast12.2.Midwest12.3.West12.4.South
13.Company Profile
13.1.Cardinal Health13.1.1.Company details13.1.2.Financial outlook13.1.3.Temperature summary13.1.4.Recent developments13.2.Cencora Corporation (ICS)13.2.1.Company details13.2.2.Financial outlook13.2.3.Temperature summary13.2.4.Recent developments13.3.CEVA Logistics13.3.1.Company details13.3.2.Financial outlook13.3.3.Temperature summary13.3.4.Recent developments13.4.DB SCHENKER13.4.1.Company details13.4.2.Financial outlook13.4.3.Temperature summary13.4.4.Recent developments13.5.EVERSANA13.5.1.Company details13.5.2.Financial outlook13.5.3.Temperature summary13.5.4.Recent developments13.6.Kerry Logistics Network Limited13.6.1.Company details13.6.2.Financial outlook13.6.3.Temperature summary13.6.4.Recent developments13.7.Knipper Health13.7.1.Company details13.7.2.Financial outlook13.7.3.Temperature summary13.7.4.Recent developments13.8.Kuehne+Nagel13.8.1.Company details13.8.2.Financial outlook13.8.3.Temperature summary13.8.4.Recent developments13.9.McKesson Corporation13.9.1.Company details13.9.2.Financial outlook13.9.3.Temperature summary13.9.4.Recent developments13.10.Thermo Fisher Scientific13.10.1.Company details13.10.2.Financial outlook13.10.3.Temperature summary13.10.4.Recent developments13.11.Others
14.Conclusion
15.List of Abbreviations
16.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
U.S Pharmaceutical Third-Party Logistics Services Marketis projected to reach USD 109.76 by 2034, growing at a CAGR of 9.15 % during the forecast period.
U.S Pharmaceutical Third-Party Logistics Services Marketsize from 2025. The Market is expected to reach USD 109.76 by 2034, at a CAGR of 9.15% during the forecast period.
U.S Pharmaceutical Third-Party Logistics Services MarketCAGR of 9.15% during the forecast period.
You can get the sample pages by clicking the link - Click Here
U.S Pharmaceutical Third-Party Logistics Services Market size is USD 109.76 from 2025 to 2034.
U.S Pharmaceutical Third-Party Logistics Services Market covered By Product Type, By Temperature, By Therapeutic Area, By Manufacture Size
The North America is anticipated to have the highest Market share in the U.S Pharmaceutical Third-Party Logistics Services Market .
"
Cardinal Health, Cencora Corporation (ICS), CEVA Logistics, DB SCHENKER, EVERSANA, Kerry Logistics Network Limited, Knipper Health, Kuehne+Nagel, McKesson Corporation, Thermo Fisher Scientific."
"
The report includes an in-depth analysis of the U.S Pharmaceutical Third-Party Logistics Services Market, including market size and trends, product mix, Applications, and supplier analysis. "
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
